Niu Xiaoshuang, Xue Fen, Liu Peiyao, Hu Chaosu, He Xiayun
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.
Transl Oncol. 2021 Dec;14(12):101216. doi: 10.1016/j.tranon.2021.101216. Epub 2021 Sep 14.
To evaluate long-term outcomes of induction chemotherapy (IC) followed by intensity-modulated radiotherapy (IMRT) and adjuvant chemotherapy (AC) in nasopharyngeal carcinoma (NPC) patients with N3 disease.
From September 2005 to August 2016, 143 patients confirmed NPC with the 8th AJCC/UICC staging criteria N3 were reviewed. All patients received IC followed by IMRT and AC.
After a median follow-up of 67 months, the 5-year and 10-year overall survival (OS), progression-free survival (PFS), distant metastasis free survival (DMFS), local progression-free survival (LPFS) and regional progression-free survival (RPFS) were 75.7% and 61.6%, 61.2% and 53.4%, 73.1% and 72.1%, 92.4% and 87%, 88.9% and 81.8%, respectively. Multivariate analyses indicated that T stage (P = 0.001) appeared to be prognostic factors for OS. T stage (P = 0.001 and P = 0.002) and neck lymph node necrosis (P = 0.015 and P = 0.045) were independent predictors of PFS and DMFS. The acute toxicities were mainly grade 1/2 hematologic toxicities in patients treated with IC+IMRT+AC, and severe toxicities were uncommon.
IC followed by IMRT and AC achieved satisfactory long-term survival outcomes in NPC patients with N3 disease. Neck lymph node necrosis and late T stage served as predictors of poor prognosis for patients.
评估诱导化疗(IC)联合调强放疗(IMRT)及辅助化疗(AC)对N3期鼻咽癌(NPC)患者的长期疗效。
回顾性分析2005年9月至2016年8月期间确诊的143例符合第8版美国癌症联合委员会/国际抗癌联盟(AJCC/UICC)分期标准的N3期NPC患者。所有患者均接受IC后序贯IMRT及AC治疗。
中位随访67个月后,5年和10年总生存率(OS)、无进展生存率(PFS)、无远处转移生存率(DMFS)、无局部进展生存率(LPFS)和无区域进展生存率(RPFS)分别为75.7%和61.6%、61.2%和53.4%、73.1%和72.1%、92.4%和87%、88.9%和81.8%。多因素分析表明,T分期(P = 0.001)似乎是OS的预后因素。T分期(P = 0.001和P = 0.002)及颈部淋巴结坏死(P = 0.015和P = 0.045)是PFS和DMFS的独立预测因素。IC+IMRT+AC治疗患者的急性毒性主要为1/2级血液学毒性,严重毒性不常见。
IC联合IMRT及AC治疗在N3期NPC患者中取得了令人满意的长期生存结果。颈部淋巴结坏死和晚期T分期是患者预后不良的预测因素。